FI3413897T3 - Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn - Google Patents

Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn Download PDF

Info

Publication number
FI3413897T3
FI3413897T3 FIEP17706102.5T FI17706102T FI3413897T3 FI 3413897 T3 FI3413897 T3 FI 3413897T3 FI 17706102 T FI17706102 T FI 17706102T FI 3413897 T3 FI3413897 T3 FI 3413897T3
Authority
FI
Finland
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
use according
administration
Prior art date
Application number
FIEP17706102.5T
Other languages
English (en)
Finnish (fi)
Inventor
Daria Hazuda
Michael D Miller
Jay A Grobler
Deborah Anne Nicoll-Griffith
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Application granted granted Critical
Publication of FI3413897T3 publication Critical patent/FI3413897T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
FIEP17706102.5T 2016-02-12 2017-02-10 Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn FI3413897T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (1)

Publication Number Publication Date
FI3413897T3 true FI3413897T3 (fi) 2023-08-25

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17706102.5T FI3413897T3 (fi) 2016-02-12 2017-02-10 Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn

Country Status (37)

Country Link
US (4) US10537589B2 (enExample)
EP (1) EP3413897B1 (enExample)
JP (4) JP6810972B2 (enExample)
KR (4) KR20250136420A (enExample)
CN (2) CN108697727A (enExample)
AU (3) AU2017217656B2 (enExample)
BR (1) BR112018016349A2 (enExample)
CA (1) CA3013473C (enExample)
CL (1) CL2018002150A1 (enExample)
DK (1) DK3413897T3 (enExample)
DO (1) DOP2018000183A (enExample)
EA (1) EA201891814A1 (enExample)
ES (1) ES2953535T3 (enExample)
FI (1) FI3413897T3 (enExample)
GE (1) GEP20217231B (enExample)
HR (1) HRP20230935T1 (enExample)
HU (1) HUE063532T2 (enExample)
IL (1) IL260874B2 (enExample)
JO (1) JOP20170038B1 (enExample)
LT (1) LT3413897T (enExample)
MD (1) MD3413897T2 (enExample)
MX (3) MX390604B (enExample)
MY (1) MY197090A (enExample)
NI (1) NI201800083A (enExample)
NZ (1) NZ745065A (enExample)
PH (1) PH12018501712A1 (enExample)
PL (1) PL3413897T3 (enExample)
PT (1) PT3413897T (enExample)
RS (1) RS64448B1 (enExample)
SG (1) SG11201806783WA (enExample)
SI (1) SI3413897T1 (enExample)
SV (1) SV2018005733A (enExample)
TN (1) TN2018000267A1 (enExample)
TW (2) TWI822652B (enExample)
UA (1) UA126375C2 (enExample)
WO (1) WO2017139519A1 (enExample)
ZA (1) ZA201805073B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
US12227536B2 (en) * 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
PH12021500034A1 (en) * 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
JP7700096B2 (ja) 2019-07-27 2025-06-30 ブリー バイオサイエンシーズ, インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
PL219609B1 (pl) 2003-02-19 2015-06-30 Masanori Baba Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
AU2020328518A1 (en) * 2019-08-13 2022-03-10 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
WO2022046578A1 (en) * 2020-08-25 2022-03-03 Merck Sharp & Dohme Corp. Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
HRP20230935T1 (hr) 2023-11-24
US20200101098A1 (en) 2020-04-02
JP2022062170A (ja) 2022-04-19
HUE063532T2 (hu) 2024-01-28
CN108697727A (zh) 2018-10-23
MX2018009763A (es) 2018-11-29
SV2018005733A (es) 2018-12-14
PL3413897T3 (pl) 2023-10-02
JP6810972B2 (ja) 2021-01-13
HK1257347A1 (en) 2019-10-18
JOP20170038B1 (ar) 2021-08-17
KR102317570B1 (ko) 2021-10-25
JP7021314B2 (ja) 2022-02-16
LT3413897T (lt) 2023-08-25
US10537589B2 (en) 2020-01-21
KR20250136420A (ko) 2025-09-16
AU2020202866A1 (en) 2020-05-21
AU2017217656A1 (en) 2018-08-23
ZA201805073B (en) 2019-05-29
RS64448B1 (sr) 2023-09-29
US20250073254A1 (en) 2025-03-06
PH12018501712A1 (en) 2019-05-15
PT3413897T (pt) 2023-08-28
US20220331350A1 (en) 2022-10-20
US11337991B2 (en) 2022-05-24
CA3013473C (en) 2021-10-26
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
AU2020202866B2 (en) 2022-04-07
NZ784982A (en) 2025-03-28
EP3413897B1 (en) 2023-06-14
KR20220126787A (ko) 2022-09-16
JP7559175B6 (ja) 2024-10-22
DOP2018000183A (es) 2018-12-31
JP2021001189A (ja) 2021-01-07
AU2022201686B2 (en) 2024-08-08
SI3413897T1 (sl) 2023-11-30
DK3413897T3 (da) 2023-09-18
CL2018002150A1 (es) 2018-12-14
MX2022002925A (es) 2023-02-10
IL260874A (enExample) 2018-09-20
MX390604B (es) 2025-03-20
MD3413897T2 (ro) 2023-11-30
EA201891814A1 (ru) 2019-01-31
BR112018016349A2 (pt) 2018-12-26
US20180055867A1 (en) 2018-03-01
MY197090A (en) 2023-05-24
UA126375C2 (uk) 2022-09-28
US12171776B2 (en) 2024-12-24
JP2019504857A (ja) 2019-02-21
JP2024001206A (ja) 2024-01-09
CN113509480A (zh) 2021-10-19
JP7559175B2 (ja) 2024-10-01
NZ745065A (en) 2023-11-24
GEP20217231B (en) 2021-03-25
EP3413897A1 (en) 2018-12-19
TN2018000267A1 (en) 2020-01-16
AU2022201686A1 (en) 2022-03-31
ES2953535T3 (es) 2023-11-14
KR20210049201A (ko) 2021-05-04
CA3013473A1 (en) 2017-08-17
TWI822652B (zh) 2023-11-21
KR20180108815A (ko) 2018-10-04
MX2022002924A (es) 2022-12-15
TW201731514A (zh) 2017-09-16
SG11201806783WA (en) 2018-09-27
TW202417010A (zh) 2024-05-01
IL260874B2 (en) 2023-10-01
WO2017139519A1 (en) 2017-08-17
IL260874B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
FI3413897T3 (fi) Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
IL263110B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2015529225A5 (enExample)
JP2019516733A5 (enExample)
NZ714963A (en) Compositions and methods for treating anemia
HRP20210901T1 (hr) Postupci pojačavanja tonične inhibicije i liječenja sekundarne nesanice
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
FI3307271T3 (fi) Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
UA96436C2 (ru) Долгосрочное лечение вич-инфекции
JP2017160178A5 (enExample)
JP2022062170A5 (enExample)
FI3355889T3 (fi) Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa
FI4212152T3 (fi) Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon
HRP20240309T1 (hr) Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
JP2019524820A5 (enExample)
FI3709996T3 (fi) Kumariinijohdannainen soluproliferaation häiriön hoitamiseksi tai ennaltaehkäisemiseksi